| Saad Khairi, MD | |
|
13345 Illinois St, Carmel, IN 46032-3318 | |
| (317) 396-1300 | |
| Not Available |
| Full Name | Saad Khairi |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 27 Years |
| Location | 13345 Illinois St, Carmel, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780685818 | NPI | - | NPPES |
| 200492310 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 01058779A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension St Vincent Hospital | Indianapolis, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indianapolis Neurosurgical Group Pc | 0941191282 | 46 |
News Archive
A possible new therapeutic target for pancreatic cancer, the most lethal form of human cancer, has been identified in the proteins whose DNA recipe comes from gene, "Seven-In-Absentia," according to researchers at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Kaiser Health News staff writer Christopher Weaver, working in collaboration with The Washington Post, reports: "For years, an obscure federal task force sifted through medical literature ranging from colonoscopies to fluoride treatment, ferreting out the best evidence for doctors to use in caring for their patients. But now its recommendations have new financial implications, raising the stakes for patients, physicians and others in the health care industry"
"Researchers say they've developed the first vaccine for visceral leishmaniasis (VL) - a disease that affects 500,000 people each year and has been called the 'parasitic version of HIV,'" although the diseases are unrelated, U.S. News reports.
Researchers at the University of Arizona Health Sciences are undertaking a study to better understand the potential enviromental and occupational health risks specific to women in the fire service.
› Verified 5 days ago
| Entity Name | Indianapolis Neurosurgical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275580318 PECOS PAC ID: 0941191282 Enrollment ID: O20040324000655 |
News Archive
A possible new therapeutic target for pancreatic cancer, the most lethal form of human cancer, has been identified in the proteins whose DNA recipe comes from gene, "Seven-In-Absentia," according to researchers at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Kaiser Health News staff writer Christopher Weaver, working in collaboration with The Washington Post, reports: "For years, an obscure federal task force sifted through medical literature ranging from colonoscopies to fluoride treatment, ferreting out the best evidence for doctors to use in caring for their patients. But now its recommendations have new financial implications, raising the stakes for patients, physicians and others in the health care industry"
"Researchers say they've developed the first vaccine for visceral leishmaniasis (VL) - a disease that affects 500,000 people each year and has been called the 'parasitic version of HIV,'" although the diseases are unrelated, U.S. News reports.
Researchers at the University of Arizona Health Sciences are undertaking a study to better understand the potential enviromental and occupational health risks specific to women in the fire service.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Saad Khairi, MD 13345 Illinois St, Carmel, IN 46032-3318 Ph: (317) 396-1300 | Saad Khairi, MD 13345 Illinois St, Carmel, IN 46032-3318 Ph: (317) 396-1300 |
News Archive
A possible new therapeutic target for pancreatic cancer, the most lethal form of human cancer, has been identified in the proteins whose DNA recipe comes from gene, "Seven-In-Absentia," according to researchers at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
Ocera Therapeutics, Inc. presented results yesterday from a Phase 2 proof-of-concept study of AST-120 (spherical carbon adsorbent) in the treatment of patients with non-constipating Irritable Bowel Syndrome (IBS) at DDW, the annual meeting of the American Gastroenterological Association. Data showed that subjects treated with AST-120 responded in a consistent manner with reduction in pain better than placebo at week four and at week eight, the primary time point for analysis. The company plans to initiate a Phase 2b study evaluating AST-120 in non-constipating IBS.
Kaiser Health News staff writer Christopher Weaver, working in collaboration with The Washington Post, reports: "For years, an obscure federal task force sifted through medical literature ranging from colonoscopies to fluoride treatment, ferreting out the best evidence for doctors to use in caring for their patients. But now its recommendations have new financial implications, raising the stakes for patients, physicians and others in the health care industry"
"Researchers say they've developed the first vaccine for visceral leishmaniasis (VL) - a disease that affects 500,000 people each year and has been called the 'parasitic version of HIV,'" although the diseases are unrelated, U.S. News reports.
Researchers at the University of Arizona Health Sciences are undertaking a study to better understand the potential enviromental and occupational health risks specific to women in the fire service.
› Verified 5 days ago
Dr. Eric M. Horn, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 13345 Illinois St, Carmel, IN 46032 Phone: 317-396-1300 Fax: 317-352-3417 | |
Jean-pierre Mobasser, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 13345 Illinois St, Carmel, IN 46032 Phone: 317-396-1300 Fax: 317-352-3417 | |
Kenneth L. Renkens Jr., M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 13225 N Meridian St, Carmel, IN 46032 Phone: 317-228-7000 Fax: 317-228-2321 | |
Dr. Shannon Mccanna, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 13345 Illinois St, Carmel, IN 46032 Phone: 317-396-1300 Fax: 317-396-1346 | |
Eric A Potts, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 13345 Illinois St, Carmel, IN 46032 Phone: 317-396-1300 Fax: 317-396-1163 | |
Terry G. Horner, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 10767 Illinois St Ste 3000, Carmel, IN 46032 Phone: 317-817-1200 Fax: 317-817-1220 | |
Carl J Sartorius, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 13345 Illinois St, Carmel, IN 46032 Phone: 317-396-1300 Fax: 317-352-3417 |